Focal Segmental Glomerulosclerosis 6 (FSGS6) Cell Models for Research

Focal Segmental Glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome in adults and children, with an estimated incidence of 7 per million in the US and higher in certain populations. FSGS6 is a specific genetic form caused by mutations in the COL4A4 gene, which encodes type IV collagen alpha 4 chain. The disease progresses to end-stage renal disease (ESRD) in a significant proportion of patients, with 5-year renal survival rates varying by genetic cause and treatment response. Risk factors include family history, ethnicity (higher in African Americans), and certain genetic variants. According to the WHO, chronic kidney diseases, including FSGS, contribute to a growing global burden, with ESRD requiring dialysis or transplantation.

FSGS6 is an ideal model for studying podocyte biology and glomerular filtration barrier function. The disease has clear genetic etiology, making it amenable to gene editing. Public datasets such as the Nephrotic Syndrome Study Network (NEPTUNE) provide comprehensive clinical and molecular data. Open questions include the mechanisms of podocyte injury, the role of COL4A4 mutations in disease progression, and the development of targeted therapies. Gene-edited cell models are crucial for dissecting these pathways and testing potential drugs.

FSGS6 is primarily caused by mutations in COL4A4, leading to defects in the glomerular basement membrane (GBM). The major pathways involved include:

• • GBM Assembly: COL4A4 forms heterotrimers with COL4A3 and COL4A5, and mutations disrupt the collagen network, weakening the GBM.
• • Podocyte Signaling: Altered GBM integrity triggers podocyte stress pathways, including integrin signaling, actin cytoskeleton remodeling, and apoptosis.
• • Inflammatory and Fibrotic Pathways: Chronic podocyte injury leads to activation of TGF-beta signaling, promoting glomerulosclerosis and interstitial fibrosis.
• • Mitochondrial Dysfunction: Some studies suggest mitochondrial dysfunction contributes to podocyte injury in FSGS.

Data from ClinVar and COSMIC.

Key signaling networks deregulated in FSGS6 include:

• • Integrin Signaling: Integrin alpha3/beta1 and alphaV/beta3 are key mediators of podocyte-GBM interaction. Mutations in COL4A4 disrupt this signaling, leading to podocyte detachment.
• • PI3K/AKT Pathway: This pathway is often hyperactivated in response to podocyte injury, promoting survival but also contributing to hypertrophy and sclerosis.
• • TGF-beta/Smad Pathway: TGF-beta is a major driver of fibrosis and is upregulated in FSGS.
• • Wnt/beta-catenin Pathway: Aberrant activation has been implicated in podocyte dedifferentiation and epithelial-mesenchymal transition.
• • Notch Pathway: Notch signaling is involved in podocyte development and injury response.

Organoids offer a more physiologically relevant 3D model, recapitulating glomerular and tubular structures, and are useful for studying cell-cell interactions and drug responses.

Animal models for FSGS6 include:

• • Col4a4 knockout mice: These mice develop progressive glomerulosclerosis and proteinuria, mimicking human FSGS6.
• • Col4a4 knock-in mice: Mice with specific patient mutations (e.g., G325R) show similar phenotypes.
• • Induced models: Adriamycin or puromycin aminonucleoside (PAN) nephropathy models are used to induce podocyte injury, though they are not genetic models.
• • Zebrafish models: Transient knockdown of col4a4 has been used to study glomerular development.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise mutations in COL4A4 or other FSGS-related genes. For example:

• • COL4A4 knockout podocyte cell lines: These lines lack functional COL4A4, allowing study of GBM assembly and podocyte function.
• • COL4A4 point mutation knock-in lines: Specific patient mutations (e.g., G325R) can be introduced to study their impact on protein function and cellular phenotype.
• • Reporter lines: GFP-tagged podocyte-specific proteins (e.g., nephrin) can be used to monitor slit diaphragm integrity.

These models are commercially available from various sources and are sequence-verified, ensuring reproducibility. They are essential for drug screening and functional genomics.

Gene-edited cell models are used to validate the function of genes implicated in FSGS6. For example:

• • Knockout lines: Knocking out COL4A4 in podocytes can reveal its role in cell adhesion and survival.
• • Knock-in lines: Introducing disease-associated mutations allows assessment of their impact on protein localization and function.
• • CRISPR screens: Genome-wide knockout screens in podocytes can identify modifiers of COL4A4-related phenotypes.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput drug screening. For FSGS6, these models can be used to:

• • Identify compounds that rescue podocyte injury in COL4A4 mutant cells.
• • Test drugs that modulate GBM integrity or podocyte signaling pathways.
• • Study mechanisms of resistance to current therapies (e.g., corticosteroids) and identify alternative treatments.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the context of COL4A4 mutations. This can lead to the discovery of novel biomarkers and therapeutic targets. For example, targeting genes involved in the unfolded protein response or mitochondrial function may be selectively lethal to mutant cells.